Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...

Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) prolonged ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...

After selling out in barely 48 hours when it launched earlier this month, Lenovo has re-stocked the Legion Tab, its small yet powerful Android tablet. The Lenovo Legion Tab was announced at CES as ...

You’ll find both the Galaxy Tab S9 and S9 FE running Android 14 with the One UI 6 skin on top. This has proven a great software package on the pricier tablets, packing more multitasking features ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient patients seeing a 14-month gain and 38% lower death risk. New final overall ...

The addition of LuPSMA to enzalutamide reduced the risk of death by 45% vs enzalutamide alone. The median OS was 34 months (95% CI, 30-37) with the combination compared to 26 months (95% CI, 23-31) ...

We don't expect to see new Galaxy Tab or OnePlus Pad models until a bit later in the year, but hopefully the Qualcomm Snapdragon 8 Elite chipset that's creating waves in the Android versus iOS ...

Mevrometostat combined with enzalutamide improved median rPFS to 14.3 months versus 6.2 months with enzalutamide alone in mCRPC patients. The combination therapy showed a higher objective response ...

Talazoparib and enzalutamide combination significantly improved overall survival in mCRPC patients compared to enzalutamide and placebo. The TALAPRO-2 study showed a median overall survival of 45.8 ...